IVERIC bio announces fast track designation from US FDA for Zimura to treat geographic atrophy secondary to dry age-related macular degeneration

IVERIC bio announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Zimura® (avacincaptad pegol), a novel complement C5 inhibitor, in development for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD).